^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 836858

    i
    Associations
    News

    Trials

    Company:
    Boehringer Ingelheim
    Drug class:
    CD33 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse (NCT01690624)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    05/23/2018
    Initiation :
    09/13/2012
    Primary completion :
    05/21/2018
    Completion :
    05/21/2018
    CD33
    |
    CD33 positive
    |
    BI 836858